OFFICE OF THE DIRECTOR
Kate Brown, Governor

Oregon Health Authority

500 Summer St NE E20
Salem OR 97301
Voice: 503-947-2340
Fax: 503-947-2341
www.Oregon.Gov/OHA
www.health.oregon.gov

OFFICIAL WEBSITE NOTICE
Posting Date: May 29, 2019

RECOMMENDATIONS OF DRUG USE REVIEW / PHARMACY AND THERAPEUTICS COMMITTEE

The Oregon Drug Use Review / Pharmacy and Therapeutics Committee met in Salem, Oregon on Thursday, May 23, 2019. The Committee considered in order of priority: the safety and efficacy of the drugs being considered, the ability of Oregonians to access effective prescription drugs that are appropriate for their clinical conditions and finally, substantial differences in costs of drugs within the same therapeutic class. Based upon the clinical information presented by staff [i] and all public comment offered,[ii] while considering the impact on special populations, the Committee makes the following recommendations for the Oregon Practitioner-Managed Prescription Drug Plan (PMPDP) or for any other preferred drug list established by the Oregon Health Authority:

Drug Use Review Recommendations:

Gonadotropin-Releasing Hormone (GnRH) Modifiers

The Committee recommended adding the class to the PMPDP and designate all agents as non-preferred.

Combination Biologic Therapy Drug Use Evaluation (DUE)

The Committee recommended updating the prior authorization (PA) criteria to include a maximum dose for patients with rheumatoid arthritis prescribed tofacitinib and to reinforce periodic tuberculosis testing. The Committee also recommended developing a retrospective drug utilization review (RetroDUR) provider education on disease-modifying antirheumatic drug (DMARD) adherence.

Attention Deficit Hyperactivity Disorder (ADHD) DUE

The Committee recommended to continue to monitor use of ADHD medications and consider provider education on importance of diagnosis and assessment for patients with treatment-resistant ADHD symptoms and those at an increased risk of substance misuse.

The Committee also recommended staff perform an evaluation of concomitant stimulant and antipsychotic medications prescribing.

Schizophrenia RetroDUR Proposal

The Committee recommended implementation of a retrospective initiative to notify providers when patients on routine therapy for schizophrenia miss a medication refill.

Practitioner-Managed Prescription Drug Plan (PMPDP) Recommendations:

Asthma / Chronic Obstructive Pulmonary Disease (COPD) Class Update and New Drug Evaluation (NDE)

The Committee recommended making clerical revisions to PA criteria to remove references to guideline classifications of COPD and recommended no changes to the PMPDP based on clinical evidence. After comparative cost consideration in executive session, the Committee recommended making Dulera, Tudorza, and Asmanex preferred on the PMPDP.

DRUG	CHANGE
Dulera®	Make preferred on the PMPDP
Tudorza®	Make preferred on the PMPDP
Asmanex	Make preferred on the PMPDP

Migraine Treatment and Prevention Drug Effectiveness Review Project (DERP) Summary

The Committee recommended making no changes to the PMPDP based on review of the evidence. After comparative cost consideration in executive session, the Committee recommended making sumatriptan succinate syringes and zolmitriptan tablets, rapid tablets and nasal spray preferred on the PMPDP.

DRUG	CHANGE
sumatriptan succinate syringe	Make preferred on the PMPDP
zolmitriptan tablets	Make preferred on the PMPDP
zolmitriptan rapid tablets	Make preferred on the PMPDP
zolmitriptan nasal spray	Make preferred on the PMPDP

Calcitonin gene-related peptide Inhibitors DERP Summary

The Committee recommended making no changes to the PMPDP based on review of the evidence, but to change the duration of approval for renewal criteria to 6 months. After comparative cost consideration in executive session, the Committee recommended making no changes to the PMPDP and maintaining all agents in the class as non-preferred.

Potassium Exchangers Class Update

The Committee recommended adding sodium zirconium cyclosilicate to the patiromer PA criteria, to change the duration of the initial and renewal approval to 3 months, and to remove the requirement for trial and failure of kayexlate. After comparative cost consideration in executive session, the Committee recommended making patiromer non-preferred and maintaining sodium zirconium cyclosilicate as non-preferred on the PMPDP.

DRUG	CHANGE
Patiromer	Make non-preferred on the PMPDP

Other Dyslipidemia Drugs Class Update

The Committee recommended updating the PA criteria as proposed to be consistent with the new evidence for use of non-statins to prevent atherosclerotic cardiovascular disease events, retire the PA criteria for lomitapide and mipomersen due to no utilization, and to make gemfibrozil non-preferred due to safety concerns with use in combination with statin therapy. After comparative cost consideration in executive session, the Committee recommended making ezetimibe and evolocumab preferred.

DRUG	CHANGE
Ezetimibe	Make preferred on the PMPDP
Evolocumab	Make preferred on the PMPDP

The Committee has made these recommendations to the Oregon Health Authority for approval by the Director of the Oregon Health Authority.

APPROVAL BY THE DIRECTOR OF THE OREGON HEALTH AUTHORITY

The recommendations of the Drug Use Review / Pharmacy and Therapeutics Committee are approved. Recommendations with respect to the inclusion of a drug on the Practitioner-Managed Prescription Drug Plan will be put into place no earlier than 7 days from the date this notice is posted on the web site.

Patrick M. Allen
Director

May 29, 2019
Approval date

A request for reconsideration of this decision to adopt the recommendations of the Drug Use Review / Pharmacy and Therapeutics Committee must be filed with and received by the Director no later than 7 calendar days from the date of this notice. 2019 OR law, HB 2692

[i] https://www.orpdl.org/durm/meetings/meetingdocs/2019_05_23/finals/2019_05_23_PnT_Complete.pdf
[ii] https://www.orpdl.org/durm/meetings/meetingdocs/2019_05_23/finals/2019_05_23_WrittenTestimony.pdf